Zacks Investment Research upgraded shares of 3SBIO INC-ADS (SSRX) from UNDERPERFORM to NEUTRAL on January 18, 2013, with a target price of $13.70.
3SBIO INC. is a leading, fully integrated biotechnology company focused on researching, developing, manufacturing and marketing biopharmaceutical products, primarily in China. The Company's protein-based products and product candidates are designed to address markets with medical needs in nephrology, oncology, supportive cancer care, inflammation and infectious diseases. The Company's diversified product pipeline includes a number of protein-based therapeutics, including NuPIAO, its second-generation EPIAO product candidate NuLeusin, its next-generation Inleusin product candidate TPIAO for the treatment of idiopathic thrombocytopenic purpura, a human papilloma virus vaccine for the prevention of cervical cancer, and an anti-tumor necrosis factor humanized monoclonal antibody product candidate for the treatment of rheumatoid arthritis and other autoimmune diseases.
Get all Zacks Research Reports and be alerted to fast-breaking buy and sell opportunities every trading day.
To get a free copy of the research report on 3SBIO INC-ADS (SSRX),
click here.
For more information about research offerings from Zacks Investment Research, visit
Zacks.com .
Be the first to comment